Uptake and Excretion of a Single Dose of Oral 14C-labelled Polystyrene Microplastics in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-19

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to understand how a small, labeled dose of microplastics moves through the human body (i.e., how it is absorbed, distributed, and excreted) in healthy adult volunteers aged 18-65 years (3 males, 3 females). The main questions it aims to answer are:

* How much of the ingested microplastic is absorbed into the bloodstream?
* How is the microplastic distributed and eliminated from the body through urine and feces?

Participants will:

* Take a single oral micro dose of 100 µg of 1 μm \[14C\]-labelled polystyrene microplastics (PS-MP).
* Spend 24 hours in a clinical research facility for close monitoring and initial sample collection.
* Provide blood, urine, and stool samples over a 5-day period (with daily short lab visits after the first day).

This study does not include a comparison group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

NCT01442831

Healthy

COMPLETED PHASE1

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293

NCT02126514

Healthy Volunteers Mass Balance Study

COMPLETED PHASE1

A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers

NCT01711762

Healthy Volunteer

COMPLETED PHASE1

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

NCT04183686

Healthy

COMPLETED PHASE1

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

NCT03795519

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Human exposure to micro- and nanoplastics (MNPs) is increasingly recognized, yet their internal behavior in the body-absorption, distribution, and elimination-is still not well understood. No human data currently exist to support toxicokinetic modeling, which is essential for translating laboratory (in vitro) data into risk assessments. This study addresses this gap by quantifying the biokinetics of a single oral microdose of 1 μm \[14C\]-labelled polystyrene microplastics in healthy volunteers. By using Accelerator Mass Spectrometry (AMS), extremely low concentrations of radiolabeled particles can be accurately measured in biological matrices (blood, urine, and feces). This will provide critical benchmark data to validate in vitro-to-in vivo extrapolations and improve human health risk assessments for microplastics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kinetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single arm

\[14C\]-labelled PS-MP ingestion

Group Type EXPERIMENTAL

1 μm [14C]-labelled Polystyrene Microplastic

Intervention Type DRUG

A single test day during which participants will orally ingest a single micro dose of 100 μg 1 µm \[14C\]-labelled PS-MP. Prior to and following ingestion of the labelled PS-MP, biological samples (i.e. blood, urine, faeces) will be collected at regular intervals, throughout the 5-day study period. Participants will spend the first 24h in the clinical laboratory, after which they are allowed to spend the remainder of the 5-day study period at home but with daily visits to the laboratory for blood sampling and home collection of urine and faeces.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1 μm [14C]-labelled Polystyrene Microplastic

A single test day during which participants will orally ingest a single micro dose of 100 μg 1 µm \[14C\]-labelled PS-MP. Prior to and following ingestion of the labelled PS-MP, biological samples (i.e. blood, urine, faeces) will be collected at regular intervals, throughout the 5-day study period. Participants will spend the first 24h in the clinical laboratory, after which they are allowed to spend the remainder of the 5-day study period at home but with daily visits to the laboratory for blood sampling and home collection of urine and faeces.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males and females using contraception during and for 3 months after the study.
* Aged from 18-65 years at the time of signing informed consent
* 18.5 \< BMI \< 25 kg·m-2
* Must be willing and able to communicate and participate in the whole study
* Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)

Exclusion Criteria

* Diabetes (Type 1, Type 2, or genetic form of diabetes)
* Any diagnosed cardiovascular (heart) disease or high blood pressure (≥140 mmHg systolic and/or ≥90 mmHg diastolic)
* History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastro-intestinal disease, immunodeficiency, endocrine, neurological or psychiatric disorders
* Known severe kidney problems
* Subjects who have regular gastrointestinal complaints including abdominal pain, stomach upsets and borborygmi, known or suspected irritable bowel syndrome, or functional constipation
* Recent or chronic history of diarrhoea
* Known anaemia
* Known impaired liver function
* A personal or family history of thrombosis (clots), epilepsy, seizures, or schizophrenia.
* Chronic use of any prescribed or over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices)
* History of any drug or alcohol abuse in the past two years
* A confirmed positive alcohol breath test at screening or admission
* Any known food allergies or intolerances to the 14 major food allergens (celery, cereals containing gluten, crustaceans, eggs, fish, lupin, milk, molluscs, mustard, tree nuts, peanuts, sesame seeds, soybeans, sulphur dioxide and sulphites) or history of a malabsorption syndrome including coeliac disease
* Currently taking part in other scientific research
* Having received a product with 14C in the past 12 months
* Pregnant or breastfeeding
* Subjects who have taken antibiotics within the 60 days prior to the adaptation period.
* Unable to give consent
* Employed or undertaking a thesis or internship at the department of Human and Animal Physiology

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes